Market Report Source

Overview

The patient populations for neuropathic and nociceptive pain are large, and are driven by separate disease trends that necessitate pain relief; across the seven major markets in 2005 it was estimated that 37.6m individuals suffered from neuropathic pain and 170.1m suffered from nociceptive pain. The major constituents of the neuropathic pain market are lower back pain, neuralgia/fibromyalgia, diabetic neuropathic pain and pain associated with multiple sclerosis. The nociceptive pain market is driven by the prevalence of the major indications of arthritic pain, particularly osteoarthritis and rheumatoid arthritis, post-operative pain, cancer-related pain and HIV-related pain. Current management of pain is mostly pharmacological consisting of the use of opioids, non-opioids and non-steroidal anti-inflammatory drugs (NSAIDs), as well as adjuvant therapies such as anti-depressants and anti-convulsants. Although pain is not a new phenomenon, misdiagnosis and under-treatment continue to prove deleterious to the pain market. Increased education for patients, physicians, nurses and pharmacists is an on-going unmet need that must be addressed. Across the seven major markets, it is forecast that the prevalence of both the neuropathic and nociceptive markets will increase modestly. It is forecast that the prevalence of the neuropathic pain market will increase to 39.1m individuals, which is complimented by the forecast growth of the nociceptive market to include 164.8m individuals in 2011.

Table of Contents

Table of Contents

The Pain Market Outlook to

Executive Summary

Patient potential

Global market analysis

Analysis of potential future blockbusters

Leading players in the global pain market

Chapter 1 Patient potential

Summary

Introduction

Neuropathic pain

Lower back pain

Background

Diagnosis, treatment and management

Epidemiology

Neuralgia/fibromyalgia

Background

Diagnosis, treatment and management

Epidemiology

Diabetic neuropathic pain

Background

Diagnosis, treatment and management

Epidemiology

Pain associated with multiple sclerosis

Background

Diagnosis, treatment and management

Epidemiology

Nociceptive pain

Arthritic pain

Background

Diagnosis, treatment and management

Epidemiology

Post-operative pain

Background

iv

Diagnosis, treatment and management

Epidemiology

Cancer-related pain

Background

Diagnosis, treatment and management

Epidemiology

HIV related pain

Background

Diagnosis, treatment and management

Epidemiology

Chapter 2 Global market analysis

Summary

Introduction

Pain market analysis

Leading brands in the global pain market

Opioid market analysis

Leading brands in the global opioid market

Long-acting opioid market analysis

Key brands analysis

Short-acting opioid market analysis

Key brands analysis

Class sales forecast to 2011

Non-opioid market analysis

Leading brands in the non-opioid market

Key brands analysis

Class sales forecast to 2011

Non-steroidal anti-inflammatory drugs

Leading brands in the NSAID market

Key brands analysis

Class sales forecast to 2011

Cox-II inhibitor market analysis

Leading brands in the COX-II inhibitor market

Key brands analysis

Class sales forecast to 2011

Anti-convulsants market analysis

Leading brands in the anti-convulsant market

First-generation anti-convulsants

Key brands analysis

Second-generation anti-convulsants

Key brands analysis

Class sales forecast to 2011

Global pain market forecasts to 2011

v

Chapter 3 Analysis of potential future blockbusters

Summary

Introduction

Major approaches to R&D

Leading drugs in development

Drug profiles

Phase II pipeline drugs

NW-1029 (ralfinamide)

Phase III pipeline drugs

Tapentadol (CG5503/R33133)

Bicifadine

Transacin (NGX-4010)

Neurodex (dectromorphan/quinidine)

Chronogesic (sufentanil)

Lacosamide

M6G (morphine-6-glucuronide)

Licofelone (ML3000)

Recently marketed drugs

Lyrica (pregabalin)

Prialt (ziconotide)

IONSYS (fentanyl iontophoretic transdermal system)

DepoDur (morphine)

Prexige (lumiracoxib)

Forecast sales potential

Chapter 4 Leading players in the global pain market

Summary

Introduction

Global market shares

Pfizer

Marketed products

R&D compounds

Pain portfolio forecasts to 2011

Johnson & Johnson

Marketed products

R&D compounds

Pain portfolio forecasts to 2011

Novartis

vi

Marketed products

R&D compounds

Pain portfolio forecasts to 2011

GlaxoSmithKline

Marketed products

R&D compounds

Pain portfolio forecasts to 2011

Mundipharma Int.

Marketed products

R&D compounds

Pain portfolio forecasts to 2011

Abbott

Marketed products

R&D compounds

Pain portfolio forecasts to 2011

Boehringer Ingelheim

Marketed products

R&D compounds

Pain portfolio forecasts to 2011

Sanofi-Aventis

Marketed products

R&D compounds

Pain portfolio forecasts to 2011

Chapter 5 Appendix

IMS sales data

Index

Glossary

vii

List of Figures

Figure 1.1: Types of diabetic neuropathy

Figure 1.2: Types of pain in multiple sclerosis

Figure 1.3: Types of nociceptive cancer-related pain

Figure 1.4: Sources of nociceptive HIV-related pain

Figure 2.5: Competitive dynamics of the global pain market by drug class, 2005

Figure 2.6: Competitive dynamics of the leading products in the global pain market, 2005

Figure 2.7: Competitive dynamics of the leading opioid products in the global pain market,

Figure 2.8: Competitive dynamics of the leading non-opioid products in the global pain market,

2005

Figure 2.9: Competitive dynamics of the leading NSAID products in the global pain market,

Figure 2.10: Competitive dynamics of the leading COX-II inhibitor brands in the global pain

market, 2005

Figure 2.11: Competitive dynamics of the leading anti-convulsant products in the global pain

market, 2005

Figure 3.12: Leading recently launched products and late-stage R&D compounds indicated for the

treatment of pain, 2006

Figure 4.13: Key players in the global pain market, 2001 and 2005

List of Tables

Table 1.1: Estimated prevalence of neuropathic and nociceptive pain in the seven major

pharmaceutical markets, 2005

Table 1.2: Estimated prevalence of neuropathic lower back pain in the seven major

pharmaceutical markets, 2005

Table 1.3: Forecast prevalence of neuropathic lower back pain across the seven major markets,

2005–11

Table 1.4: Estimated prevalence of neuralgia/fibromyalgia pain in the seven major

pharmaceutical markets, 2005

Table 1.5: Forecast prevalence of neuralgia/fibromyalgia across the seven major markets, 2005–

11

Table 1.6: Estimated prevalence of diabetic neuropathic pain (DNP) in the seven major

pharmaceutical markets, 2005

Table 1.7: Forecast prevalence of diabetic neuropathic pain across the seven major markets,

2005–11

Table 1.8: Estimated prevalence of multiple sclerosis (MS) in the seven major pharmaceutical

markets, 2005

Table 1.9: Forecast prevalence of pain associated with multiple sclerosis across the seven major

markets, 2005–11

Table 1.10: Estimated prevalence of OA-related pain in the seven major pharmaceutical markets,

2005

Table 1.11: Estimated prevalence of RA pain in the seven major pharmaceutical markets, 2005

viii

Table 1.12: Forecast prevalence of OA and RA related pain across the seven major markets, 2005–

11

Table 1.13: Estimated prevalence of post-operative pain in the seven major pharmaceutical

markets, 2005

Table 1.14: Forecast prevalence of post-operative pain across the seven major markets, 2005–11

Table 1.15: Estimated prevalence of cancer-related pain in the seven major pharmaceutical

markets, 2005

Table 1.16: Forecast prevalence of cancer-related pain across the seven major markets, 2005–11

Table 1.17: Estimated prevalence of HIV-related pain in the seven major pharmaceutical markets,

2005

Table 1.18: Forecast prevalence of HIV-related pain across the seven major markets, 2005–11

Table 2.19: Breakdown of the global pain market by drug class, 2001-05

Table 2.20: Leading brands in the global pain market, 2004–05

Table 2.21: Leading brands in the global opioid market, 2004–05

Table 2.22: Sales forecasts for opioids in the global pain market, 2005–11

Table 2.23: Leading non-opioid products in the global pain market, 2004–05

Table 2.24: Sales forecasts for non-opioids, 2005–11

Table 2.25: Leading NSAIDs in the global pain market, 2004–05

Table 2.26: Sales forecasts for NSAIDs in the global pain market, 2005–11

Table 2.27: Leading COX-II inhibitor brands in the global pain market, 2004–05

Table 2.28: Sales forecasts for COX-II inhibitors, 2005–11

Table 2.29: Leading anti-convulsant products in the global pain market, 2004–05

Table 2.30: Sales forecasts for anti-convulsants in the global pain market, 2005–11

Table 2.31: Sales forecasts in the global pain market, 2005–11

Table 3.32: Sales forecasts for key recently launched products and R&D compounds, 2005–11

Table 4.33: Key players in the global pain market, 2005

Table 4.34: Pfizer’s marketed pain portfolio, 2005

Table 4.35: Pfizer’s pain R&D pipeline, 2006

Table 4.36: Forecast sales for Pfizer’s pain portfolio, 2005-11

Table 4.37: J&J’s marketed pain portfolio, 2005

Table 4.38: J&J’s pain R&D pipeline, 2006

Table 4.39: Forecast sales for J&J’s pain portfolio, 2005–11

Table 4.40: Novartis’ marketed pain portfolio, 2005

Table 4.41: Novartis’ pain R&D pipeline, 2006

Table 4.42 Forecast sales for Novartis’ pain portfolio, 2005–11

Table 4.43 GSK’s marketed pain portfolio, 2005

Table 4.44: GSK’s pain R&D pipeline, 2006

Table 4.45: Forecast sales for GSK’s pain portfolio, 2005–11

Table 4.46: Mundipharma’s marketed pain portfolio, 2005

Table 4.47: Forecast sales for Mundipharma’s pain portfolio, 2005–11

Table 4.48: Abbott’s marketed pain portfolio, 2005

Table 4.49: Abbott’s pain R&D pipeline, 2006

Table 4.50: Forecast sales for Abbott’s pain portfolio, 2005–11

Table 4.51: Boehringer Ingelheim’s marketed pain portfolio, 2005

Table 4.52: Forecast sales for Boehringer Ingelheim’s pain portfolio, 2005–11

Table 4.53: Sanofi-Aventis’ marketed pain portfolio, 2005

Table 4.54: Sanofi-Aventis’ pain R&D pipeline, 2006

Table 4.55: Forecast sales for Sanofi-Aventis’ pain portfolio, 2005–11 197